Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 803 results for "eisai"

Infosys Helped Oil Well Experts FTS International in Strategic Enterprise Resource Planning (ERP) Transformation
APN News

Eisai Co., Ltd.: R&I Downgrades to A+/a-1, Stable

Rating and Investment Information, Inc. (R&I) has announced the following: Eisai Co., Ltd. is a pharmaceutical company with strong re & development capabilities. The company has a track record in the development of epoch-making drugs. In response ... Noodls, 22 hours ago
[x]  

102 images for eisai

Pharma Letter, 1 week ago
Pharma Letter, 5 days ago
Pharmafile, 2 weeks ago
Broadway World, 1 week ago
Drug Discovery and Development, 1 week ago
Eisai, 1 week ago
APN News, 2 weeks ago
APN News, 2 weeks ago
APN News, 2 weeks ago
APN News, 2 weeks ago
Broadway World

ACCENTURE : Eisai Inks Global IT Outsourcing Contract with Accenture

Accenture has signed a contract to provide information technology (IT) system maintenance and operations, as well as monitoring and operations of servers and networks for Eisai Co. in the U.S. and Japan . Under the contract, Accenture noted, it ...
 4 Traders1 week ago Accenture, Eisai sign global IT outsourcing contract  PharmaBiz1 week ago Eisai Inks Global IT Outsourcing Contract with Accenture  Individual.com1 week ago Accenture signs contract with Eisai to provide IT services in US and Japan  Individual.com1 week ago
[x]  

Eisai launches thyroid carcinoma drug in UK

Eisai Co., Ltd., a Japanese pharmaceutical company, has announced that its UK subsidiary, Eisai Europe Ltd., has launched its in-house developed anticancer agent, Lenvima, indicated for the treatment of adult patients with progressive, locally ...
 Individual.com2 weeks ago Eisai receives EC approval for thyroid carcinoma drug  Individual.com3 weeks ago

New Data to be Presented at the European Academy of Neurology (EAN) Congress 2015 Highlights Eisai's Commitment to Its Leading Epilepsy Portfolio

/PRNewswire/ -- PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/AUSTRIAN/US JOURNALISTS Eisai is proud to present key data from its epilepsy portfolio, the largest of its kind in the Europe, at the first European Academy of Neurology Congress ...
 Individual.com2 weeks ago June 29, 2015June 30, 2015  Prbox.com1 week ago Guidance on the Transition of Patients from Oxcarbazepine or Carbamazepine to Eslicarbazepine Acetate in Certain Clinical Situations Now Published in Epilepsy and Behaviour  Individual.com1 week ago Fycompa® (pérampanel), premier médicament de sa classe pharmaco-thérapeutique, obtient une extension d'AMM dans les crises généralisées primaires tonico-cloniques  PR Newswire1 week ago
[x]  

Eisai's Lenvima available in Austria and Germany for thyroid cancer

01-07-2015 Print Japanese drug major Eisai's Lenvima (lenvatinib) is now available in Germany and Austria for people… In order to access this content you need to be logged into the site and have an active subscription or trial ...
 Pharma Letter5 days ago People with Advanced Thyroid Cancer in Germany and Austria Now Able to Benefit from New Thyroid Cancer Treatment Lenvima® (Lenvatinib)  Sys-Con Media6 days ago People With Thyroid Cancer in The Nordic Region Now Able to Benefit From New Advanced Thyroid Cancer Treatment Lenvima(R) (Lenvatinib)  Individual.com1 week ago
[x]  

Studies from Eisai Have Provided New Data on Medicinal Chemistry [Discovery of...

Studies from Eisai Have Provided New Data on Medicinal Chemistry [Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methy1}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin ...] ...
 4 Traders5 days ago

Prefilled Syringes Market (3rd Edition), 2015 - 2025

FEATURED COMPANIES AbbVie/Eisai ARTE CORPORATION Datwyler Nipro Corporation Roselabs Group Teva Pharmaceuticals MORE 1. Preface 1.1. Scope of the Report 1.2.
 Research and Markets5 days ago
Pharma Letter

AdverseEvents analyzes leading anti-obesity drugs for risk and cost

Of several leading anti-obesity drugs, Belviq (lorgaserin hydrochloride) from Japanese drug major Eisai… In order to access this content you need to be logged into the site and have an active subscription or trial subscription. Please login , ...
 Pharma Letter5 days ago

McKesson's Paul Julian is HDMA's 2015 Nexus winner

Diana awards for Apotex, Eisai, Depomet and Bayer Healthcare in manufacturing AT HDMA's annual Leadership Conference (San Antonio, June 9-11), the association awarded Paul Julian, EVP and group president of McKesson, with its Nexus Award for ...
 Pharmaceutical Commerce6 days ago
European Pharmaceutical Review

Epilespy treatment perampanel receives marketing authorisation for primary generalised tonic-clonic seizures

The European Commission (EC) has granted marketing authorisation approval for Eisai's Fycompa (perampanel) for use as a once-daily, adjunctive therapy for primary generalised tonic-clonic (PGTC) seizures in adults and adolescents with idiopathic ...
 European Pharmaceutical Review1 week ago European Commission grants marketing authorization to Eisai's Fycompa  Pharma Letter1 week ago Fycompa (perampanel) receives European MA for PGTC seizures in patients with idiopathic generalised epilepsy  Medical News Today1 week ago First-in-class Epilepsy Treatment Fycompa® (perampanel) Receives Marketing Authorisation for Primary Generalised Tonic-clonic Seizures  Ulitzer1 week ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - eisai
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less